The diagnostic performance of patient symptoms in screening for COPD

for the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network

doi:10.1186/s12931-018-0853-5

The diagnostic performance of patient symptoms in screening for COPD

for the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network

Medicine

Research output: Contribution to journal › Letter › peer-review

6 Citations (Scopus)

Abstract

It is recommended that screening for COPD be restricted to symptomatic individuals, but supporting evidence is lacking. We determined the performance of wheeze, cough, phlegm, and dyspnea in discriminating COPD versus non-COPD in a population-based sample of 1332 adults. Area Under the Receiver Operating Curves (AUC) indicated that symptoms had modest performance whether assessed individually (AUCs 0.55-0.62), or in combination (AUC for number of symptoms as the predictor 0.64). AUC improved with the inclusion of multiple other factors (AUC 0.71). Restricting screening to symptomatic individuals is unlikely to substantially improve the yield of general population screening for undiagnosed COPD.

Original language	English
Article number	147
Journal	Respiratory Research
Volume	19
Issue number	1
DOIs	https://doi.org/10.1186/s12931-018-0853-5
Publication status	Published - Aug 3 2018

Bibliographical note

Funding Information:
The current study was funded by a Canadian Lung Association Breathing as One Studentship Award and the Canadian Institutes of Health Research (application number 142238). The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN); industry partners: Astra Zeneca Canada Ltd.; Boehringer Ingelheim Canada Ltd.; GlaxoSmithKline Canada Ltd.; and Novartis. Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners are the CIHR (CIHR/Rx&D Collaborative Research Program Operating Grants 93326); the Respiratory Health Network of the Fonds de la recherche en santé du Québec (FRSQ); industry partners: Almirall; Merck Nycomed; Pfizer Canada Ltd.; and Theratechnologies. The funders had no role in study design, data collection and analysis, or preparation of the manuscript.

Publisher Copyright:
© 2018 The Author(s).

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine

Access to Document

10.1186/s12931-018-0853-5

Cite this

for the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network (2018). The diagnostic performance of patient symptoms in screening for COPD. Respiratory Research, 19(1), Article 147. https://doi.org/10.1186/s12931-018-0853-5

@article{0509cec3b4fd4744bb635d585648df25,

title = "The diagnostic performance of patient symptoms in screening for COPD",

abstract = "It is recommended that screening for COPD be restricted to symptomatic individuals, but supporting evidence is lacking. We determined the performance of wheeze, cough, phlegm, and dyspnea in discriminating COPD versus non-COPD in a population-based sample of 1332 adults. Area Under the Receiver Operating Curves (AUC) indicated that symptoms had modest performance whether assessed individually (AUCs 0.55-0.62), or in combination (AUC for number of symptoms as the predictor 0.64). AUC improved with the inclusion of multiple other factors (AUC 0.71). Restricting screening to symptomatic individuals is unlikely to substantially improve the yield of general population screening for undiagnosed COPD.",

author = "{for the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network} and Johnson, {Kate M.} and Tan, {Wan C.} and Jean Bourbeau and Sin, {Don D.} and Mohsen Sadatsafavi and Qutayba Hamid and Carole Jabet and Palmina Mancino and Li, {Pei Zhi} and Zhi Song and Yvan Fortier and Andrea Benedetti and Dennis Jensen and David Latreille and Jacinthe Baril and Laura Labont{\'e} and {Mark FitzGerald}, J. and Harvey Coxson and Darcy Marciniuk and Ron Clemens and Janet Baran and O'Donnell, {Dennis E.} and Denis O'Donnell and Matthew McNeil and Kate Whelan and Paul Hernandez and Scott Fulton and Kristen Osterling and Chapman, {Kenneth R.} and Teresa To and Andrea Gershon and Kenneth Chapman and Patricia McClean and Nadeen Audisho and Robert Cowie and R. Cowie and B. Walter and Ann Cowie and Curtis Dumonceaux and Lisette Machado and Shawn Aaron and Kathy Vandemheen and Gay Pratt and Amanda Bergeron and F. Maltais and Jonathon Samet and Milo Puhan and Christine Lo and Sarah Cheng and Cindy Fung",

note = "Funding Information: The current study was funded by a Canadian Lung Association Breathing as One Studentship Award and the Canadian Institutes of Health Research (application number 142238). The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN); industry partners: Astra Zeneca Canada Ltd.; Boehringer Ingelheim Canada Ltd.; GlaxoSmithKline Canada Ltd.; and Novartis. Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners are the CIHR (CIHR/Rx&D Collaborative Research Program Operating Grants 93326); the Respiratory Health Network of the Fonds de la recherche en sant{\'e} du Qu{\'e}bec (FRSQ); industry partners: Almirall; Merck Nycomed; Pfizer Canada Ltd.; and Theratechnologies. The funders had no role in study design, data collection and analysis, or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = aug,

day = "3",

doi = "10.1186/s12931-018-0853-5",

language = "English",

volume = "19",

journal = "Respiratory Research",

issn = "1465-9921",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - The diagnostic performance of patient symptoms in screening for COPD

AU - for the Canadian Cohort of Obstructive Lung Disease (CanCOLD) study and the Canadian Respiratory Research Network

AU - Johnson, Kate M.

AU - Tan, Wan C.

AU - Bourbeau, Jean

AU - Sin, Don D.

AU - Sadatsafavi, Mohsen

AU - Hamid, Qutayba

AU - Jabet, Carole

AU - Mancino, Palmina

AU - Li, Pei Zhi

AU - Song, Zhi

AU - Fortier, Yvan

AU - Benedetti, Andrea

AU - Jensen, Dennis

AU - Latreille, David

AU - Baril, Jacinthe

AU - Labonté, Laura

AU - Mark FitzGerald, J.

AU - Coxson, Harvey

AU - Marciniuk, Darcy

AU - Clemens, Ron

AU - Baran, Janet

AU - O'Donnell, Dennis E.

AU - O'Donnell, Denis

AU - McNeil, Matthew

AU - Whelan, Kate

AU - Hernandez, Paul

AU - Fulton, Scott

AU - Osterling, Kristen

AU - Chapman, Kenneth R.

AU - To, Teresa

AU - Gershon, Andrea

AU - Chapman, Kenneth

AU - McClean, Patricia

AU - Audisho, Nadeen

AU - Cowie, Robert

AU - Cowie, R.

AU - Walter, B.

AU - Cowie, Ann

AU - Dumonceaux, Curtis

AU - Machado, Lisette

AU - Aaron, Shawn

AU - Vandemheen, Kathy

AU - Pratt, Gay

AU - Bergeron, Amanda

AU - Maltais, F.

AU - Samet, Jonathon

AU - Puhan, Milo

AU - Lo, Christine

AU - Cheng, Sarah

AU - Fung, Cindy

N1 - Funding Information: The current study was funded by a Canadian Lung Association Breathing as One Studentship Award and the Canadian Institutes of Health Research (application number 142238). The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network (CRRN); industry partners: Astra Zeneca Canada Ltd.; Boehringer Ingelheim Canada Ltd.; GlaxoSmithKline Canada Ltd.; and Novartis. Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners are the CIHR (CIHR/Rx&D Collaborative Research Program Operating Grants 93326); the Respiratory Health Network of the Fonds de la recherche en santé du Québec (FRSQ); industry partners: Almirall; Merck Nycomed; Pfizer Canada Ltd.; and Theratechnologies. The funders had no role in study design, data collection and analysis, or preparation of the manuscript. Publisher Copyright: © 2018 The Author(s).

PY - 2018/8/3

Y1 - 2018/8/3

N2 - It is recommended that screening for COPD be restricted to symptomatic individuals, but supporting evidence is lacking. We determined the performance of wheeze, cough, phlegm, and dyspnea in discriminating COPD versus non-COPD in a population-based sample of 1332 adults. Area Under the Receiver Operating Curves (AUC) indicated that symptoms had modest performance whether assessed individually (AUCs 0.55-0.62), or in combination (AUC for number of symptoms as the predictor 0.64). AUC improved with the inclusion of multiple other factors (AUC 0.71). Restricting screening to symptomatic individuals is unlikely to substantially improve the yield of general population screening for undiagnosed COPD.

AB - It is recommended that screening for COPD be restricted to symptomatic individuals, but supporting evidence is lacking. We determined the performance of wheeze, cough, phlegm, and dyspnea in discriminating COPD versus non-COPD in a population-based sample of 1332 adults. Area Under the Receiver Operating Curves (AUC) indicated that symptoms had modest performance whether assessed individually (AUCs 0.55-0.62), or in combination (AUC for number of symptoms as the predictor 0.64). AUC improved with the inclusion of multiple other factors (AUC 0.71). Restricting screening to symptomatic individuals is unlikely to substantially improve the yield of general population screening for undiagnosed COPD.

UR - http://www.scopus.com/inward/record.url?scp=85051077871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051077871&partnerID=8YFLogxK

U2 - 10.1186/s12931-018-0853-5

DO - 10.1186/s12931-018-0853-5

M3 - Letter

C2 - 30075717

AN - SCOPUS:85051077871

SN - 1465-9921

VL - 19

JO - Respiratory Research

JF - Respiratory Research

IS - 1

M1 - 147

ER -

The diagnostic performance of patient symptoms in screening for COPD

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this